FGFR3 and breast cancer: Improper activation of this gene (by mutations in the coding sequence or by alterations in its regulatory pathways) is present in 60% of BC samples, as underlined for example in studies of tissue microarrays [134, 135]; indeed, FGFR3 improper function is a typical feature of NMIBC [136].